We are live on ! Find out more
TXMD icon

TherapeuticsMD

82 hedge funds and large institutions have $442M invested in TherapeuticsMD in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 43 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

981% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $146K

153% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 17

15% more capital invested

Capital invested by funds: $384M → $442M (+$58.8M)

0.03% more ownership

Funds ownership: 1.19%1.22% (+0.03%)

6% less funds holding

Funds holding: 8782 (-5)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
82
Holders Change
-5
Holders Change %
-5.75%
% of All Funds
2.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
43
Reduced
17
Closed
12
Calls
$1.58M
Puts
$146K
Net Calls
+$1.43M
Net Calls Change
+$1.17M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$101M +$7.31M +29,011 +7%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$88.5M +$12M +47,764 +14%
Bank of New York Mellon
3
Bank of New York Mellon
New York
$47.8M +$12.2M +48,469 +31%
GGHC
4
Gilder Gagnon Howe & Co
New York
$28.3M -$201K -799 -0.7%
Massachusetts Financial Services
5
Massachusetts Financial Services
Massachusetts
$22.3M -$552K -2,191 -2%
State Street
6
State Street
Massachusetts
$20.5M +$15.2M +60,446 +218%
BFA
7
BlackRock Fund Advisors
California
$17.2M +$686K +2,723 +4%
Franklin Resources
8
Franklin Resources
California
$16.3M -$661K -2,624 -4%
RCM
9
RA Capital Management
Massachusetts
$16M -$4.28M -16,974 -20%
Vanguard Group
10
Vanguard Group
Pennsylvania
$14.3M +$1.4M +5,576 +10%
Millennium Management
11
Millennium Management
New York
$10.6M +$1.19M +4,720 +12%
Northern Trust
12
Northern Trust
Illinois
$5.52M +$1.05M +4,150 +21%
BIT
13
BlackRock Institutional Trust
California
$5.29M +$127K +506 +2%
GH
14
GAM Holding
Switzerland
$5.09M +$1.66M +6,571 +43%
Lord, Abbett & Co
15
Lord, Abbett & Co
New Jersey
$4.02M +$1.4M +5,543 +47%
VM
16
VHCP Management
New York
$3.93M
GTC
17
Ghost Tree Capital
New York
$3.48M +$2.52M +10,000 +200%
CCP
18
Clough Capital Partners
Massachusetts
$3.39M +$310K +1,229 +9%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$2.79M +$532K +2,113 +21%
SIP
20
Stoneridge Investment Partners
Pennsylvania
$2.1M +$154K +610 +7%
Goldman Sachs
21
Goldman Sachs
New York
$2.01M +$2.07M +8,224 +1,869%
TCIM
22
TIAA CREF Investment Management
New York
$1.75M -$50.1K -199 -3%
New York State Common Retirement Fund
23
New York State Common Retirement Fund
New York
$1.54M
BIM
24
BlackRock Investment Management
Delaware
$1.45M +$114K +451 +8%
Charles Schwab
25
Charles Schwab
California
$1.42M +$330K +1,309 +27%

TXMD Hedge Fund Activity: Q3 2014 in Review

82 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2014, worth a combined $442M — up 15% from $384M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of TXMD and 7 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 43 added.

The largest buyer was State Street, adding an estimated $15.2M. The largest seller was Century Capital Management, exiting entirely with an estimated $8.43M sold.

  • 82 institutional investors held TherapeuticsMD (TXMD) as of Q3 2014, down from 87 in Q2 2014.
  • Funds reported $442M of TherapeuticsMD stock for Q3 2014, up 15% quarter-over-quarter.
  • 7 funds opened new TherapeuticsMD positions in Q3 2014 and 12 closed out, a net change of -5 holders.
  • The largest TherapeuticsMD buyer in Q3 2014 was State Street, an estimated $15.2M added.
  • The largest TherapeuticsMD seller in Q3 2014 was Century Capital Management, an estimated $8.43M sold.

Based on aggregated 13F filings for Q3 2014.